Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jan;42(1):94-101.
doi: 10.3174/ajnr.A6875. Epub 2020 Nov 26.

Noninvasive Determination of IDH and 1p19q Status of Lower-grade Gliomas Using MRI Radiomics: A Systematic Review

A P Bhandari  1   2 , R Liong  3 , J Koppen  2 , S V Murthy  4 , A Lasocki  5   6
Affiliations

Noninvasive Determination of IDH and 1p19q Status of Lower-grade Gliomas Using MRI Radiomics: A Systematic Review

A P Bhandari et al. AJNR Am J Neuroradiol. 2021 Jan.

Abstract

Background: Determination of isocitrate dehydrogenase (IDH) status and, if IDH-mutant, assessing 1p19q codeletion are an important component of diagnosis of World Health Organization grades II/III or lower-grade gliomas. This has led to research into noninvasively correlating imaging features ("radiomics") with genetic status.

Purpose: Our aim was to perform a diagnostic test accuracy systematic review for classifying IDH and 1p19q status using MR imaging radiomics, to provide future directions for integration into clinical radiology.

Data sources: Ovid (MEDLINE), Scopus, and the Web of Science were searched in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses for Diagnostic Test Accuracy guidelines.

Study selection: Fourteen journal articles were selected that included 1655 lower-grade gliomas classified by their IDH and/or 1p19q status from MR imaging radiomic features.

Data analysis: For each article, the classification of IDH and/or 1p19q status using MR imaging radiomics was evaluated using the area under curve or descriptive statistics. Quality assessment was performed with the Quality Assessment of Diagnostic Accuracy Studies 2 tool and the radiomics quality score.

Data synthesis: The best classifier of IDH status was with conventional radiomics in combination with convolutional neural network-derived features (area under the curve = 0.95, 94.4% sensitivity, 86.7% specificity). Optimal classification of 1p19q status occurred with texture-based radiomics (area under the curve = 0.96, 90% sensitivity, 89% specificity).

Limitations: A meta-analysis showed high heterogeneity due to the uniqueness of radiomic pipelines.

Conclusions: Radiogenomics is a potential alternative to standard invasive biopsy techniques for determination of IDH and 1p19q status in lower-grade gliomas but requires translational research for clinical uptake.

PubMed Disclaimer

Figures

FIG 1.
FIG 1.
IDH status forest plot of included studies with an AUC.
FIG 2.
FIG 2.
1p19q status forest plot of included studies with an AUC.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Stark AM, van de Bergh J, Hedderich J, et al. . Glioblastoma: clinical characteristics, prognostic factors and survival in 492 patients. Clin Neurol Neurosurg 2012;114:840–45 10.1016/j.clineuro.2012.01.026 - DOI - PubMed
    1. Louis DN, Perry A, Reifenberger G, et al. . The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol 2016;131:803–20 10.1007/s00401-016-1545-1 - DOI - PubMed
    1. Akay A, Rüksen M, Islekel S. Magnetic resonance imaging-guided stereotactic biopsy: a review of 83 cases with outcomes. Asian J Neurosurg 2019;14:90–95 10.4103/ajns.AJNS_81_17 - DOI - PMC - PubMed
    1. Lasocki A, Tsui A, Tacey MA, et al. . MRI grading versus histology: predicting survival of World Health Organization grade II-IV astrocytomas. AJNR Am J Neuroradiol 2015;36:77–83 10.3174/ajnr.A4077 - DOI - PMC - PubMed
    1. Horbinski C. What do we know about IDH 1/2 mutations so far, and how do we use it? Acta Neuropathol 2013;125:621–36 10.1007/s00401-013-1106-9 - DOI - PMC - PubMed

Publication types

Substances